Travis Gerke

Assistant Member, Moffitt Cancer Center


Dr. Gerke's active line of research lies in integrative molecular prostate cancer epidemiology, and is driven by concurrent interests in biostatistical methods development and computational biology. Several of his recent publications investigate tumor-based biomarkers that can distinguish aggressive from non-aggressive prostate cancers in large prospective cohorts. Methodological interests in this area concern ways in which high-dimensional data analysis techniques can be modified to discover markers that are highly specific for indolent cancer types. With regard to computational biology and statistics, he also collaborates on efforts to streamline processing, analysis, and epidemiologic translation of large-scale genomic databases such as The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus. Finally, an emerging research interest applies contemporary methods in causal inference to existing clinical trial data in order to discover optimal treatment sequences for metastatic castration-resistant prostate cancer